KRYS on Nasdaq
Krystal Biotech, Inc.
Biotechnology company.1
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Immunocore Holdings plc, Twist Bioscience or Tarsus Pharmaceuticals, Inc., or pick any stock.
- TickerKRYS on Nasdaq1
- Industrybiotechnology industry1
- HeadquartersPittsburgh, United States1
- Websitewww.krystalbio.com
- Business address2100 Wharton Street, Suite 701, Pittsburgh, Pa 152034
- Filer categoryLarge accelerated filer4
- Legal formCorporation3
- LEI549300YONUY68210OE413
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 63659533
See how the biggest companies compare on our leaderboards
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home by a healthcare professional, caregiver, or directly by the patient themselves. Our innovative technology platform is supported by two in-house, commercial scale Current Good Manufacturing Prac…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
41.5%Operating margin6
52.6%Net margin6
33.9%Revenue growth, 20256
16.8%Return on equity6
$188.9MFree cash flow6
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development14¢$58.0M
- Selling, general and admin35¢$146.7M
- Income tax4¢$15.4M
- Profit48¢$204.8M
Out of $389.1M in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending6¢$12.0M
- Kept or used elsewhere94¢$188.9M
Out of $200.9M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Product revenue, net | $389.1M | $290.5M | $50.7M |
| Cost of goods sold | $23.0M | $20.1M | $3.1M |
| Research and development | $58.0M | $53.6M | $46.4M |
| Selling, general and administrative | $146.7M | $113.6M | $98.3M |
| Litigation settlement | $0 | $37.5M | $12.5M |
| Total operating expenses | $227.8M | $224.8M | $160.3M |
| Income (loss) from operations | $161.3M | $65.7M | -$109.6M |
| Gain from sale of priority review voucher | $0 | $0 | $100.0M |
| Interest and other income, net | $28.2M | $29.6M | $22.5M |
| Income before income taxes | $189.5M | $95.4M | $12.9M |
| Income tax benefit (expense) | $15.4M | -$6.2M | -$2.0M |
| Net income | $204.8M | $89.2M | $10.9M |
| Unrealized gain (loss) on available-for-sale securities, net of tax | $642.0K | -$440.0K | $1.4M |
| Foreign currency translation | $684.0K | -$388.0K | -$66.0K |
| Comprehensive income | $206.2M | $88.3M | $12.3M |
| Basic (in usd per share) | $7.08 | $3.12 | $0.40 |
| Diluted (in usd per share) | $6.84 | $3.00 | $0.39 |
| Basic (in shares) | 28.9M shares | 28.6M shares | 27.2M shares |
| Diluted (in shares) | 30.0M shares | 29.7M shares | 27.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $496.3M | $344.9M | ||
| Short-term investments | $331.5M | $252.7M | ||
| Accounts receivable, net | $127.4M | $104.7M | ||
| Inventory | $40.5M | $26.5M | ||
| Prepaid taxes | $14.0M | $1.6M | ||
| Prepaid expenses and other current assets | $14.9M | $11.7M | ||
| Total current assets | $1.0B | $742.0M | ||
| Property and equipment, net | $150.8M | $155.2M | ||
| Long-term investments | $128.1M | $152.1M | ||
| Right-of-use assets | $7.2M | $6.3M | ||
| Deferred tax asset, net of valuation allowance | $22.8M | $0 | ||
| Other non-current assets | $287.0K | $231.0K | ||
| Total assets | $1.3B | $1.1B | ||
| Accounts payable | $3.2M | $5.0M | ||
| Current portion of lease liability | $1.8M | $1.2M | ||
| Accrued rebates | $58.2M | $36.8M | ||
| Accrued expenses and other current liabilities | $39.8M | $59.0M | ||
| Total current liabilities | $102.9M | $102.0M | ||
| Lease liability | $7.6M | $6.0M | ||
| Other long-term liabilities | $3.7M | $1.4M | ||
| Total liabilities | $114.2M | $109.5M | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of December 31, 2025 and 2024; 29,192 and 28,794 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | $0 | $0 | ||
| Additional paid-in capital | $1.2B | $1.1B | ||
| Accumulated other comprehensive income (loss) | $1.1M | -$190.0K | ||
| Retained earnings (accumulated deficit) | $24.2M | -$180.7M | ||
| Total stockholders equity | $1.2B | $946.4M | $778.6M | $522.2M |
| Total liabilities and stockholders equity | $1.3B | $1.1B | ||
| Common stock, par value (in usd per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 80.0M shares | 80.0M shares | ||
| Common stock, shares issued (in shares) | 29.2M shares | 28.8M shares | ||
| Common stock, shares outstanding (in shares) | 29.2M shares | 28.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $496.3M | $344.9M | ||
| Short-term investments | $331.5M | $252.7M | ||
| Accounts receivable, net | $127.4M | $104.7M | ||
| Inventory | $40.5M | $26.5M | ||
| Prepaid taxes | $14.0M | $1.6M | ||
| Prepaid expenses and other current assets | $14.9M | $11.7M | ||
| Total current assets | $1.0B | $742.0M | ||
| Property and equipment, net | $150.8M | $155.2M | ||
| Long-term investments | $128.1M | $152.1M | ||
| Right-of-use assets | $7.2M | $6.3M | ||
| Deferred tax asset, net of valuation allowance | $22.8M | $0 | ||
| Other non-current assets | $287.0K | $231.0K | ||
| Total assets | $1.3B | $1.1B | ||
| Accounts payable | $3.2M | $5.0M | ||
| Current portion of lease liability | $1.8M | $1.2M | ||
| Accrued rebates | $58.2M | $36.8M | ||
| Accrued expenses and other current liabilities | $39.8M | $59.0M | ||
| Total current liabilities | $102.9M | $102.0M | ||
| Lease liability | $7.6M | $6.0M | ||
| Other long-term liabilities | $3.7M | $1.4M | ||
| Total liabilities | $114.2M | $109.5M | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of December 31, 2025 and 2024; 29,192 and 28,794 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | $0 | $0 | ||
| Additional paid-in capital | $1.2B | $1.1B | ||
| Accumulated other comprehensive income (loss) | $1.1M | -$190.0K | ||
| Retained earnings (accumulated deficit) | $24.2M | -$180.7M | ||
| Total stockholders equity | $1.2B | $946.4M | $778.6M | $522.2M |
| Total liabilities and stockholders equity | $1.3B | $1.1B | ||
| Common stock, par value (in usd per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 80.0M shares | 80.0M shares | ||
| Common stock, shares issued (in shares) | 29.2M shares | 28.8M shares | ||
| Common stock, shares outstanding (in shares) | 29.2M shares | 28.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $204.8M | $89.2M | $10.9M |
| Gain from sale of priority review voucher | $0 | $0 | -$100.0M |
| Deferred tax asset | -$22.8M | $0 | $0 |
| Depreciation | $5.7M | $6.0M | $5.0M |
| Accretion of marketable securities | -$498.0K | -$1.7M | -$2.2M |
| Amortization of operating lease right-of-use assets | $827.0K | $747.0K | $904.0K |
| Stock-based compensation expense, net | $54.5M | $49.1M | $39.9M |
| Realized gain on investments | -$6.0M | -$6.1M | -$5.1M |
| Other, net | $684.0K | $652.0K | $217.0K |
| Accounts receivable, net | -$22.1M | -$62.7M | -$42.0M |
| Inventory | -$6.3M | -$11.9M | -$4.5M |
| Prepaid taxes | -$12.4M | -$1.6M | $0 |
| Prepaid expenses and other assets | -$2.3M | -$7.3M | -$1.6M |
| Lease liability | -$578.0K | -$833.0K | -$829.0K |
| Other long-term liabilities | $2.3M | $1.4M | $0 |
| Accounts payable | $826.0K | $1.0M | -$101.0K |
| Accrued rebates | $21.3M | $30.8M | $6.0M |
| Accrued expenses and other current liabilities | $14.1M | $5.4M | $4.6M |
| Accrued legal settlement | -$31.2M | $31.2M | $0 |
| Net cash provided by (used in) operating activities | $200.9M | $123.4M | -$88.8M |
| Proceeds from disposal of assets | $435.0K | $0 | $0 |
| Proceeds from sale of priority review voucher | $0 | $0 | $100.0M |
| Purchases of property and equipment | -$12.0M | -$4.2M | -$11.8M |
| Purchases of investments | -$422.5M | -$457.7M | -$508.8M |
| Maturities of investments | $375.6M | $298.5M | $503.2M |
| Net cash (used in) provided by investing activities | -$58.4M | -$163.4M | $82.6M |
| Proceeds from issuance of common stock, net | $0 | $0 | $159.7M |
| Proceeds from exercise of stock options | $22.7M | $32.4M | $43.8M |
| Net cash provided by financing activities | $8.7M | $27.0M | $202.8M |
| Effect of exchange rate changes on cash and cash equivalents | $286.0K | -$458.0K | -$156.0K |
| Net change in cash and cash equivalents | $151.4M | -$13.5M | $196.4M |
| Unpaid purchases of property and equipment | $3.1M | $8.5M | $8.6M |
| Initial recognition of right-of-use assets | $1.8M | $0 | $0 |
| Income taxes paid | $15.7M | $5.7M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Krystal Biotech, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerKrish S. Krishnan Sep 19, 2017 to now14
- PresidentSuma Krishnan Mar 1, 2022 to now15
- PresidentKrish S. Krishnan Sep 19, 2017 to Mar 1, 202214
- Chief financial officerAnthony A. Riley May 24, 2018 to Nov 21, 201916
- Chief operating officerSuma Krishnan Sep 19, 2017 to Dec 14, 202117
Board members and other officers (14)
- EVP, Head of InternationalLaurent Louis Jean Goux Mar 6, 2026 to now18
- Chief Business OfficerJing L. Marantz Jan 31, 2022 to Jan 31, 202219
- Chief Commercial OfficerAndrew C. Orth May 11, 2021 to Jun 9, 202320
- Chief Commercial OfficerJennifer Chien Jan 31, 2020 to Feb 4, 202021
- Chief Accounting OfficerKathryn Romano Feb 25, 2020 to now22
- Board memberEverett Rand Sutherland Jan 26, 2022 to now23
- Board memberJing L. Marantz Jan 5, 2021 to Jul 2, 202124
- Board memberJulian S. Gangolli Mar 6, 2019 to now25
- Board memberDaniel Janney Sep 19, 2017 to now26
- Board memberDino A. Rossi Sep 19, 2017 to now27
- Board memberKirti Ganorkar Sep 19, 2017 to Sep 19, 201728
- Board memberKrish S. Krishnan Sep 19, 2017 to now14
- Board memberR. Douglas Norby Sep 19, 2017 to Jun 4, 201829
- Board memberSuma Krishnan Sep 19, 2017 to now17
Timeline
Filings
311 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 64 major events, 122 insider forms, 26 large holders, 79 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 20264 EDGAR
- Aug 3, 20268-K EDGAR
- Aug 3, 202610-Q EDGAR
- Jul 21, 20268-K EDGAR
- Jun 26, 20264 EDGAR
- Jun 25, 2026144 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
The 311 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
82 open-market trades by officers, directors and large owners since October 2021: 0 buys and 82 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Krishnan SumaPresident, R&D | Sale | 25,000 | $359.32 | $9.0M | Form 4 |
| Sep 4, 2026 | Krishnan Krish SPresident and CEO | Sale | 25,000 | $359.32 | $9.0M | Form 4 |
| Aug 14, 2026 | ROSSI DINO ADirector | Sale | 25,000 | $329.12 | $8.2M | Form 4 |
| Jun 25, 2026 | Thomas John CharlesEVP, General Counsel | Sale | 1,000 | $347.27 | $347.3K | Form 4 |
| Jun 4, 2026 | Krishnan SumaPresident, R&D | Sale | 25,000 | $308.12 | $7.7M | Form 4 |
| Jun 4, 2026 | Krishnan Krish SPresident and CEO | Sale | 25,000 | $308.12 | $7.7M | Form 4 |
| May 26, 2026 | Thomas John CharlesEVP, General Counsel | Sale | 642 | $302.03 | $193.9K | Form 4 |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sale | 25,000 | $263.21 | $6.6M | Form 4 |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sale | 25,000 | $263.17 | $6.6M | Form 4 |
| Mar 2, 2026 | ROMANO KATHRYNChief Accounting Officer | Sale | 750 | $267.60 | $200.7K | Form 4 |
| Feb 27, 2026 | JANNEY DANIELDirector | Sale | 11,803 | $275.59 | $3.3M | Form 4 |
| Feb 26, 2026 | JANNEY DANIELDirector | Sale | 7,741 | $275.63 | $2.1M | Form 4 |
| Feb 25, 2026 | JANNEY DANIELDirector | Sale | 700 | $275.00 | $192.5K | Form 4 |
| Feb 24, 2026 | JANNEY DANIELDirector | Sale | 51,720 | $267.27 | $13.8M | Form 4 |
| Feb 19, 2026 | ROSSI DINO ADirector | Sale | 18,950 | $261.41 | $5.0M | Form 4 |
| Feb 9, 2026 | ROMANO KATHRYNChief Accounting Officer | Sale | 12,500 | $272.14 | $3.4M | Form 4 |
| Dec 4, 2025 | Krishnan SumaPresident, R&D | Sale | 50,000 | $220.15 | $11.0M | Form 4 |
| Dec 4, 2025 | Krishnan Krish SPresident and CEO | Sale | 50,000 | $220.15 | $11.0M | Form 4 |
| Jul 16, 2025 | Krishnan SumaPresident, R&D | Sale | 2,918 | $150.00 | $437.7K | Form 4 |
| Jul 16, 2025 | Krishnan Krish SPresident and CEO | Sale | 2,918 | $150.00 | $437.7K | Form 4 |
All 82 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Krish S. KrishnanSCHEDULE 13G/A, 1 filing May 4, 202630
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202631
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Feb 13, 2024 to Mar 27, 202632
- State Street CorporationSCHEDULE 13G, 2 filings Oct 16, 2024 to Feb 5, 202533
- Redmile Group, LLCSC 13G/A, 4 filings Feb 14, 2022 to Nov 14, 202434
- FMR LLCSC 13G/A, 6 filings Feb 9, 2022 to Nov 12, 202435
- Avoro Capital Advisors LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202436
- Point72 Asset Management, L.P.SC 13G/A, 3 filings Dec 6, 2021 to Feb 14, 202337
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 4,418,197 | $1.6B | 0.1% | +44,210 |
| BlackRock, Inc. | 4,181,432 | $1.6B | 0.0% | +240,976 |
| Avoro Capital Advisors LLC | 2,888,888 | $1.1B | 9.6% | No change |
| Vanguard Portfolio Management LLC | 1,574,905 | $585.3M | 0.0% | +118,178 |
| State Street Corp | 1,351,158 | $502.2M | 0.0% | +36,724 |
| Vanguard Capital Management LLC | 1,240,567 | $461.1M | 0.0% | +75,243 |
| Soleus Capital Management, L.P. | 939,254 | $349.1M | 12.0% | −213,833 |
| Capital World Investors | 777,843 | $289.1M | 0.0% | −46,877 |
| Geode Capital Management, LLC | 698,993 | $259.8M | 0.0% | +55,018 |
| Hood River Capital Management LLC | 663,375 | $246.6M | 1.8% | +43,789 |
| Redmile Group, LLC | 632,005 | $234.9M | 15.8% | −41,500 |
| William Blair Investment Management, LLC | 570,153 | $211.9M | 0.6% | +162,975 |
| Frazier Life Sciences Management, L.P. | 481,307 | $178.9M | 3.9% | No change |
| Dimensional Fund Advisors LP | 476,038 | $176.9M | 0.0% | +7,048 |
| First Trust Advisors LP | 324,900 | $120.8M | 0.1% | −25,621 |
| Invesco Ltd. | 324,755 | $120.7M | 0.0% | +73,382 |
| Goldman Sachs Group Inc | 298,841 | $111.1M | 0.0% | +83,892 |
| Northern Trust Corp | 283,784 | $105.5M | 0.0% | +31,321 |
| Franklin Resources Inc | 261,917 | $97.3M | 0.0% | +82,652 |
| Norges Bank | 259,030 | $96.3M | 0.0% | New |
| Jupiter Topco LLC | 256,665 | $95.4M | 0.0% | New |
| Bank Of America Corp /de/ | 256,431 | $95.3M | 0.0% | −4,216 |
| Charles Schwab Investment Management Inc | 254,828 | $94.7M | 0.0% | +12,842 |
| Morgan Stanley | 235,491 | $87.5M | 0.0% | +26,409 |
| Vanguard Fiduciary Trust Co | 189,528 | $70.4M | 0.0% | +10,367 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Dec 12, 2022 | Christopher L. Jacobs, House | Buy | $1,001 - $15,000 | +266.5% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Links
- Websitewww.krystalbio.com1
- X (Twitter)x.com/KrystalBiotech1
- LinkedInwww.linkedin.com/company/krystal-biotech-inc1
- WikidataQ124665205
- SEC EDGARCIK 1711279
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARSuma Krishnan, President
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGARJing L. Marantz, Board member
- 25SEC EDGARJulian S. Gangolli, Board member
- 26SEC EDGARDaniel Janney, Board member
- 27SEC EDGARDino A. Rossi, Board member
- 28SEC EDGARKirti Ganorkar, Board member
- 29SEC EDGARR. Douglas Norby, Board member
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37